Vertex Pharmaceuticals advances suzetrigine, a potential new class of pain medicine, with FDA Fast Track and Breakthrough Therapy designations, following positive Phase 3 results.
Vertex Pharmaceuticals (VRTX) announced advancements in its suzetrigine pain program, a potential first new class of medicine for acute and neuropathic pain in over two decades. Suzetrigine, an oral selective NaV1.8 pain signal inhibitor, received a rolling New Drug Application (NDA) submission for moderate-to-severe acute pain after positive Phase 3 results. The FDA has granted it Fast Track and Breakthrough Therapy designations. Vertex is on track to complete the submission in the second quarter of 2024.
April 18, 2024
7 Articles